Neuraxis is a biotechnology business based in the US. Neuraxis shares (NRXS) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $1.95 – an increase of 14.71% over the previous week. Neuraxis employs 21 staff and has a trailing 12-month revenue of around $2.7 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.95 |
|---|---|
| 52-week range | $1.33 - $3.78 |
| 50-day moving average | $2.13 |
| 200-day moving average | $2.69 |
| Wall St. target price | $4.75 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.22 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.6 from 2025-04-17
| 1 week (2025-04-15) | -5.88% |
|---|---|
| 1 month (2025-03-21) | -30.74% |
| 3 months (2025-01-23) | -47.02% |
| 6 months (2024-10-23) | -45.95% |
| 1 year (2024-04-22) | -49.61% |
|---|---|
| 2 years (2023-04-19) | N/A |
| 3 years (2022-04-19) | N/A |
| 5 years (2020-04-19) | N/A |
| Revenue TTM | $2.7 million |
|---|---|
| Gross profit TTM | $2.3 million |
| Return on assets TTM | -169.85% |
| Return on equity TTM | -2480.49% |
| Profit margin | 0% |
| Book value | $0.30 |
| Market Capitalization | $11.5 million |
TTM: trailing 12 months
We're not expecting Neuraxis to pay a dividend over the next 12 months.
You may also wish to consider:
NeurAxis, Inc. , a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022.